RudaCure Inc., una empresa especializada en el desarrollo de nuevos fármacos, fue seleccionada para the Grand Prize at 'Core Innovación Korea 2024' hosted by Kookmin Ilbo and Cookie News.
Unlike existing tratamientos, RudaCure developed a tratamiento de la enfermedad de ojo seco RCI001 that shortens drug exposure duration through excellent producción lagrimal, daño corneal recovery, antiinflamatorio, and efectos antioxidantees.
RCI001 demonstrates therapeutic effects within 24 weeks, and is reconocido for overcoming the slow onset and efectos secundarios (hyperemia, hemorrhage, elevated presión intraocular, burning upon instillation) of existing tratamientos. It also addresses the limitations of steroid-based tratamientos, enabling long-term use and resolving existing mercado discomfort.
RudaCure planea complete nacional Phase 1 ensayo clínicos by 2024, and conduct nacional and US Phase 2 ensayo clínicos in 2025-2026. It also planea actively pursue global transferencia de tecnología through overseas clinical data.
